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Background: Clopidogrel non-responsiveness is known to be associated with major adverse cardiac event in patients undergoing percutaneous 
coronary intervention. Its mechanism is not well studied yet and studies have reported that there are inter-racial differences. In this study, we sought 
to determine genetic and clinical predictors of clopidogrel non-responsiveness in Korean population.
Methods: From June 2006 through January 2009 platelet reactivity was measured using VerifyNow P2Y12 assay in 1545 consecutive patients who 
underwent coronary angiography. With patients’ agreement, genetic analysis was performed in 538 patients. Nonresponsiveness to clopidogrel was 
defined as P2Y12 reaction unit (PRU) greater than 275, which was a cut-off value derived from a separate study with 1-year survival analysis. Genetic 
and clinical characteristics were compared between responders and non-responders.
Results: Clopidogrel non-responders comprised 35.9% of total study population. They were older, and more likely to have hypertension, diabetes, 
chronic renal failure, congestive heart failure, and calcium channel blocker use. Serum creatinine and C-reactive protein levels were higher in non-
responders. Male sex, current smoking, and hydrophilic statin use were more associated with responsiveness. With regard to genetic polymorphisms, 
patients with CYP2C19 AA genotype had higher PRU (254.5±66.7) than those with GG or GA genotype (226.4±77.0), while polymorphisms of CYP3A4 
and CYP1A2 were not statically associated with PRU. Multivariable analysis showed that female sex (OR 3.378, p<0.001), CYP2C19*2 (AA) genotype 
(OR 2.744, p<0.016), diabetes (OR 2.305, p < 0.001), serum creatinine (OR 1.982, p=0.044), CRP (1.167, p=0.046) were independently associated 
with non-reponsiveness, while the use of hydrophilic statin had negative association (OR 0.432, p=0.022).
Conclusions: In Korean population, independent clinical and genetic predictors of clopidogrel non-responsiveness included female sex, 
CYP2C19*2 AA genotype, diabetes, increased serum creatinine and CRP. The use of hydrophilic statin was associated with better responsiveness to 
clopidogrel.
